Arca Biopharma Sees Delay In Covid: 19 therapy data, shares fall

Oruka Therapeutics

13/07/2021 15:31

** Drug developer's shares  ABIO.O  fall 9.7% to $3.33
    ** Co says data from mid-stage study of its COVID-19
therapy, AB201, to be released in Q4 vs prior target of Q2     
    ** Attributes delay to trial expansion to S.America, after
securing regulatory approvals in Argentina and Brazil
 urn:newsml:reuters.com:*:nGNX98qPKF
    ** Trial target enrollment being increased to 160 patients
from 100 - ABIO
    ** Co has enrolled 77 patients in U.S. and anticipates
enrolling first S. American patients in July 2021
    ** U.S. FDA in Nov. granted "fast-track" status to AB201 as
a potential treatment for COVID-19
    ** Stock down ~17% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))